Virpax Pharmaceuticals confirms results with U.S. Army with Probudur

Virpax Pharmaceuticals (VRPX) announced the completion of the full study that followed the initial Probudur pilot study performed by the U.S. Army Institute of Surgical Research, USAISR, under an existing Cooperative Research and Development Agreement, CRADA. This study was designed to determine if Probudur reduces pain behaviors in a rat model of incisional pain. The surgical procedures and assessments were identical to those in the pilot study. The study compared Probudur with free bupivacaine and EXPAREL. Various concentrations of Probudur were injected into the tissue around the incision site as well as a saline solution for the control group. The doses of Probudur showed reduction in incision-induced pain behaviors. “These positive results are consistent with what we at Virpax have previously observed and we are encouraged by these findings,” commented Jatinder Dhaliwal, Chief Executive Officer of Virpax.